🧮 RADX Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For RADX, the trailing twelve month revenue is $3.6M.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
RADX's revenue growth rate of N/A (based on log-linear regression of 0 quarters) indicates relatively flat or slightly declining sales.
Revenue vs Profitability Metrics
Free Cash Flow: $0 →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: N/A →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $N/A →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $-38.3M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
RADX's P/S ratio of 12.7x means investors pay $12.71 for every $1 of annual revenue. A P/S above 10 indicates very high growth expectations.
Gross Margin: Revenue Quality
Gross margin of N/A shows how much of RADX's revenue remains after direct costs.
Summary: RADX Revenue Trend
Radiopharm Theranostics Limited (RADX) generated $3.6M in trailing twelve-month revenue, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring. Gross margin: N/A. For complete financial analysis, view the full RADX stock report on Zyberno.
Frequently Asked Questions
What is RADX's current revenue?
Radiopharm Theranostics Limited's trailing twelve month (TTM) revenue is $3.6M, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.
Is RADX's revenue growing?
Radiopharm Theranostics Limited (RADX) generated $3.6M in trailing twelve-month revenue, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring. Gross margin: N/A.
What is RADX's gross margin?
RADX's gross margin is N/A.
What is RADX's Price/Sales ratio?
RADX's P/S ratio is 12.7x, meaning the market values the company at 12.7 times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. RADX's revenue is $3.6M with a net income of $-38.3M, showing a net profit margin of -1,055.3%.
📊 Full RADX Stock Report →
See RADX's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 RADX Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 RADX Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 RADX Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 RADX Earnings Surprise (SUE) →
See whether RADX is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 RADX Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 RADX Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 RADX Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 RADX Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.